Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.40 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168811 | 0.83 | MLNR (0.40) | MLNRCYP2D6 | |
| SCHEMBL3097058 | 0.82 | NNMT (0.49) | JAK2JAK1JAK3HRH3OPRM1 | |
| SCHEMBL3694737 | 0.77 | HRH3 (0.65) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3077258 | 0.72 | HRH3 (0.67) | JAK2JAK1JAK3HRH3MLNR | |
| SCHEMBL3689547 | 0.70 | HRH3 (0.60) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3691171 | 0.70 | HRH3 (0.60) | HRH3OPRM1OPRD1OPRK1 | |
| SCHEMBL3077653 | 0.70 | HRH3 (0.67) | HRH3OPRM1OPRD1OPRK1MLNR | |
| SCHEMBL5181701 | 0.68 | NNMT (0.46) | MLNRCYP2D6 | |
| SCHEMBL15995001 | 0.68 | NNMT (0.53) | — | |
| SCHEMBL5161291 | 0.67 | MLNR (0.39) | JAK2JAK1JAK3HRH3MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | disclosed |
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | BAMFORD MARK JAMES | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105226-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIN2C, GRIN2A, GRIN2B | JAK2 2528/4885JAK1 3031/4885JAK3 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.